Gyre Therapeutics (GYRE) EBITDA Margin (QoQ) (2010 - 2026)

Gyre Therapeutics (GYRE) EBITDA Margin (QoQ) (2010 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Gyre Therapeutics 708.31 Mn 685.47 Mn 26.90 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -781.00
Mar 31, 2026 -4,186.00
Dec 31, 2025 -2,234.00
Sep 30, 2025 1,455.00
Jun 30, 2025 -220.00
Mar 31, 2025 792.00
Dec 31, 2024 -1,422.00
Sep 30, 2024 395.00
Jun 30, 2024 -1,704.00
Mar 31, 2024 36,723.00
Dec 31, 2023 -37,736.00
Sep 30, 2023 2,288.00
Jun 30, 2023 -977.00
Mar 31, 2023 4,886.00
Mar 31, 2022 -100,584.00
Dec 31, 2021 25,172.00
Sep 30, 2021 66,180.00
Jun 30, 2021 -22,967.00
Mar 31, 2021 -60,184.00
Dec 31, 2020 87,524.00